Compare · BNTX vs IVVD
BNTX vs IVVD
Side-by-side comparison of BioNTech SE (BNTX) and Invivyd Inc. (IVVD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and IVVD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $28.65B, about 103.5x IVVD ($276.7M).
- Over the past year, BNTX is up 8.8% and IVVD is down 11.2% - BNTX leads by 20.0 points.
- IVVD has been more active in the news (13 items in the past 4 weeks vs 7 for BNTX).
- BNTX has more recent analyst coverage (25 ratings vs 7 for IVVD).
- Company
- BioNTech SE
- Invivyd Inc.
- Price
- -
- -
- Market cap
- $28.65B
- $276.7M
- 1M return
- +25.06%
- +52.84%
- 1Y return
- +8.83%
- -11.19%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2021
- News (4w)
- 7
- 13
- Recent ratings
- 25
- 7
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Latest BNTX
- SEC Form 6-K filed by BioNTech SE
- BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
- SEC Form 6-K filed by BioNTech SE
- SEC Form 6-K filed by BioNTech SE
- BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
- SEC Form 6-K filed by BioNTech SE
- BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
- Amendment: SEC Form 20-F/A filed by BioNTech SE
- SEC Form 6-K filed by BioNTech SE
- European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
Latest IVVD
- Chief Financial Officer Duke William E. converted options into 102,000 shares and sold $31,671 worth of shares (40,780 units at $0.78) as part of a pre-agreed trading plan, increasing direct ownership by 57% to 168,937 units (SEC Form 4) (for withholding tax)
- Chief Human Resources Officer Green Julie converted options into 102,000 shares and sold $31,671 worth of shares (40,780 units at $0.78) as part of a pre-agreed trading plan, increasing direct ownership by 57% to 168,937 units (SEC Form 4) to satisfy tax liability
- Chief Scientific Officer Allen Robert D. Iii sold $29,296 worth of shares (37,722 units at $0.78) as part of a pre-agreed trading plan and converted options into 102,000 shares, increasing direct ownership by 56% to 178,765 units (SEC Form 4) to satisfy withholding tax
- Chief Legal Officer, Secretary Andersen Jill converted options into 170,000 shares and sold $52,781 worth of shares (67,962 units at $0.78) as part of a pre-agreed trading plan, increasing direct ownership by 56% to 283,774 units (SEC Form 4) to satisfy withholding obligation
- Chief Commercial Officer Lee Timothy Edward sold $31,671 worth of shares (40,780 units at $0.78) as part of a pre-agreed trading plan and converted options into 102,000 shares, increasing direct ownership by 52% to 178,937 units (SEC Form 4) (for tax liability)
- SEC Form 144 filed by Invivyd Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Invivyd Inc.
- SEC Form 10-Q filed by Invivyd Inc.
- Invivyd Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights